HDV News & Analysis

Vir Biotechnology (VIR) Trading at $11.09 and P/E Ratio of 5.92

Vir Biotechnology, Inc. (VIR) shares were trading at $11.09 as of April 20th, with a trailing P/E ratio of 5.92. The company is focusing on Chronic Hepatitis Delta (HDV) and its oncology platform, with Phase 2 data indicating a 77% Target Not Detected (TND) rate. Regulatory uncertainties could affect their 2027 BLA timeline. Financially, VIR holds $781 million in cash, providing a runway into late 2027, although dilution risks exist ahead of key data releases in Q1 2027, which could significantly impact valuation.